Dubai
English
Request a call
Book
Raw Material
USA
Purity
99%
Country of Origin
UAE
Indications
Overweight
Eating disorders
Type 2 diabetes mellitus
Support in combination therapy with GLP-1
Contraindications
Oncological processes
History of pancreatitis
Pregnancy and lactation
Individual intolerance
Cagrilintide is a high-concentration version of the peptide engineered to rapidly activate satiety pathways and recalibrate food-intake regulation. With near-immediate bioavailability, this form engages amylin receptors much faste...
Cagrilintide is a high-concentration version of the peptide engineered to rapidly activate satiety pathways and recalibrate food-intake regulation. With near-immediate bioavailability, this form engages amylin receptors much faster than pen formats, suppressing impulsive hunger signals and aligning the body’s daily energy balance from the very first doses.
The peptide engages AMY1/AMY3 receptors to strengthen both central and peripheral satiety mechanisms, helping curb overeating, stabilize caloric response, and regulate sensitivity to food triggers. This format is particularly effective at the start of therapy, when a strong metabolic shift and pronounced appetite control are needed quickly. Cagri is ideal for patients requiring an accelerated therapeutic onset - those with emotional overeating, impaired satiety signaling, high food reactivity, or resistance to weight-loss attempts. It is incorporated into active weight-management programs, combination therapies with GLP-1 agonists, and behavioral reset protocols, enabling faster appetite control and more predictable long-term progress.
The peptide engages AMY1/AMY3 receptors to strengthen both central and peripheral satiety mechanisms, helping curb overeating, stabilize caloric response, and regulate sensitivity to food triggers. This format is particularly effective at the start of therapy, when a strong metabolic shift and pronounced appetite control are needed quickly. Cagri is ideal for patients requiring an accelerated therapeutic onset - those with emotional overeating, impaired satiety signaling, high food reactivity, or resistance to weight-loss attempts. It is incorporated into active weight-management programs, combination therapies with GLP-1 agonists, and behavioral reset protocols, enabling faster appetite control and more predictable long-term progress.
Smart Benefits.
Maximum Impact.
Special Offers
The Science of Longevity in Detail
You may also like
Fill out the form to book your consultation.
Your personal manager will contact you within 10 minutes and arrange a convenient time for your visit.
